Airsculpt Technologies, Inc.

AIRS
About the company

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.

Country: United StatesPrice: $0.84Market Cap: $61.9M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

0 / 14

NEUTRAL / FAIL

Median fair value

$0.15

-82.7% vs price

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2401 (Top 77.5%)FAILFAILFAILFAILFAILFAILFAILPASSPASSFAILFAILFAILFAIL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A-318.5%N/AN/AN/A-830.0%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 7✗ 21▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.6x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-8.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-76.4%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)17.4x
      ✗Dreman< 8x
      Price / Book Value per Share0.6x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-2.4%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=1.1%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.6x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share78.0x
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($0.84)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-15.19%; #4390/6340 (top 69.2%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+1.7121; #788/6449 (top 12.2%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-9.4%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+2.3866; #957/5247 (top 18.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-4.10%; #2907/4519 (top 64.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-68.30%; #5622/6202 (top 90.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.01 (2021) -> $-0.19 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency2/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-7.9%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency1/4 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 62.3% -> 59.4%, operating margin 5.0% -> -7.6%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR19.3%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag AIRS's efficiency

      Current Ratio0.85
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)0.8%
      ✗Buffett> 10%
      ROIC - WACC-9.2%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-76.4%
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.59 -> 0.55
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.85x -> 0.81x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.85
      ✗Dreman> 1.5
      Return on Invested Capital-3.9%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=5.0%; FY2024: ROIC=-0.8%; FY2025: ROIC=-6.4%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -6.4%)
      ✗SleepROIC > 12% in a majority of years
    • Valuation models0% pass✗ 2▾

      AIRS overvalued: all 2 models price fair value below $0.84 (median $0.15)

      Munger fair value$0.20
      ✗Munger-318.5% margin vs $0.84
      Ackman fair value$0.09
      ✗Ackman-830.0% margin vs $0.84
    • Profitability6% pass✓ 3✗ 32▾

      15 of 16 flag AIRS's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/8 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)2/8 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-7.4%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-7.6% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-1.3M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-8.9%
      ✗Lynch> 15%
      EBIT / Enterprise Value-8.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-76.4%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-6.23%
      ✗PiotroskiROA > 0
      ROA Change YoY-3.77% -> -6.23% (delta: -2.46%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=1.65%, ROA=-6.23%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY60.5% -> 59.4%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-8.1%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-8.9%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.6x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-9.6% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency2/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-4.7%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-8.9%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend5.0% (2023) -> -7.6% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 62.3% -> 59.4%, operating margin 5.0% -> -7.6%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-15.19%; #4390/6340 (top 69.2%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+48.12%; #708/3702 (top 19.1%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-8.87%; #3360/5226 (top 64.3%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0444; #2422/5884 (top 41.2%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/5 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts12% pass✓ 2✗ 15▾

      Split decision: 14 FAIL · 2 PASS

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2401✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (2/9)✓TempletonPASS (4/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #1474/2370 (Top 62.2%))✗NeffFAIL (1/6)✗SchlossFAIL (3/7)✗OshaughnessyFAIL (Rank #955/963 (Top 99.2%))
    • Cash Flow30% pass✓ 4✗ 8▾

      7 of 10 flag AIRS's cash flow — Buffett, Lynch, Dreman +4 more

      Free Cash Flow Proxy$-1.3M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-2.5M
      ✗LynchPositive and growing
      Operating Cash Flow$3.1M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=1.65%, ROA=-6.23%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)17.4x
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=1.1%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive6/7 years FCF positive
      ✓MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-4.7%
      ✗Ackman>= 4%
      Price / FCF per Share78.0x
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency7/7 years positive
      ✓SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-2.5M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-4.10%; #2907/4519 (top 64.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Debt & Leverage33% pass✓ 6✗ 9▾

      8 of 12 flag AIRS's debt & leverage — Graham, Buffett, Lynch +5 more

      Debt Levels0.35
      ✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      LT Debt vs Net Current AssetsLT Debt $31.2M vs NCA $-4.2M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.35, IC: -1.4x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.35
      ✗Lynch< 0.33
      Cash - Long-term Debt$-16.0M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change30.76% -> 27.01%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.85
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.35
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Interest Coverage & Debt/EBITDAIC=-1.4x, D/EBITDA=7.4x
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.35
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.3460; #2123/4210 (top 50.4%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Healthcare
    SIC Sector: Health Services
    Size: Micro Cap($61.9M)
    Revenue: $151.8M-15.8% YoY
    Net Income: $11.7M-45.5% YoY

    Financial Snapshot

    Operating Margin-7.6%
    Return on Equity-13.3%
    Debt / Equity0.64
    Current Ratio0.55
    EPS (Diluted)$-0.19
    Shares Retired−10.0% / −12.2% 2y

    Shareholder Return

    Fiscal 2025

    Issued 10.0% of shares last year, 12.2% issued over two.

    Buybacks
    —
    Dividends
    $0

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, dividends paid.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-03-14
    FY 2023
    Sources
    • 10-K · 2024-02-27
    FY 2022
    Sources
    • 10-K · 2023-03-10
    FY 2021
    Sources
    • 10-K · 2022-03-11
    Market Cap$61.9Mcurrent------$191.4Mest.$280.6Mest.$416.9Mest.$328.2Mest.$784.5Mest.
    Revenue$147.7M↓6%$31.9M↓9%$42.9M↓3%$39.4M$151.8M↓16%$180.3M↓8%$195.9M↑16%$168.8M↑27%$133.3M
    Operating Income-$7.0M↑52%-$4.1M↑58%-$29.0K↓104%-$1.8M↓13%-$11.6M↓630%-$1.6M↓116%$9.7M↑314%-$4.5M↓129%$15.8M
    Net Income-$9.4M↑48%-$7.2M↑25%-$1.1M↓88%-$2.4M↑16%-$11.7M↓46%-$8.0M↓89%-$4.2M↑71%-$14.7M↓239%$10.6M
    EPS (Diluted)--$-0.10↑33%$-0.02↓100%$-0.03↑40%$-0.19↓36%$-0.14↓75%$-0.08↑69%$-0.26↓2500%$-0.01
    Gross Margin————59.4%↓2%60.5%↓3%62.3%↓1%62.8%↓6%66.6%
    Operating Margin-4.7%↑49%-13.0%↑53%-0.1%↓104%-4.6%↓13%-7.6%↓768%-0.9%↓118%5.0%↑284%-2.7%↓123%11.8%
    ROE-8.9%↑59%———-13.3%↓30%-10.3%↓100%-5.1%↑75%-20.7%↓264%12.6%
    Total Debt$36.7M↓36%$36.7M↓36%$43.6M↓25%$44.8M↓35%$56.0M↓20%$69.7M↓3%$71.6M↓14%$83.5M↑1%$82.6M
    Shareholders' Equity$105.9M↑29%$105.9M↑29%$104.8M↑15%$100.3M↑30%$87.7M↑12%$78.2M↓5%$82.7M↑17%$70.8M↓15%$83.5M
    Current Ratio0.85↑68%0.85↑68%0.79↑24%0.75↑31%0.55↓6%0.59↓25%0.79↑5%0.75↓58%1.79
    Debt / Equity0.35↓50%0.35↓50%0.42↓34%0.45↓50%0.64↓28%0.89↑3%0.87↓27%1.18↑19%0.99
    Operating Cash Flow-$2.0M↓124%-$3.5M↓1444%-$1.2M↓125%$5.3M↑507%$3.1M↓73%$11.3M↓53%$24.0M↓2%$24.4M↓8%$26.6M
    Free Cash Flow-$2.5M↓203%-$3.7M↓814%-$1.5M↓131%$5.2M↑605%$692.0K↑126%-$2.7M↓119%$14.0M↑22%$11.5M↓41%$19.5M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Healthcare

    AIRS vs Peers — Financial Grading

    Revenue$151.8MBottom 25%
    Net Income$11.7MBottom 25%
    ROE-13.3%Bottom 25%
    D/E0.64Median
    Op. Margin-7.6%Bottom 25%
    Curr. Ratio0.55Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    HCA Healthcare, Inc.HCA$104.2B$499.05$75.6B$6.8B-112.6%-7.7113.0%0.971/95/93/71/3F-Score 64/11
    TENET HEALTHCARE CORPTHC$22.8B$286.03$21.3B$2.4B56.1%3.1216.5%1.761/94/93/73/3F-Score 65/11
    Guardant Health, Inc.GH$20.5B$151.70$982.0M$416.3M419.2%-15.14-44.5%4.842/91/91/70/3F-Score 52/11
    EXACT SCIENCES CORPEXAS$20.0B$104.91$3.2B$207.9M-8.7%0.00-6.4%2.432/91/93/70/3F-Score 73/11
    Fresenius Medical Care AGFMS$11.4B$22.03$23.1B$1.1B7.4%0.819.3%1.265/92/91/70/3F-Score 85/11
    UNIVERSAL HEALTH SERVICES INCUHS$11.2B$194.07$17.4B$1.5B20.5%0.6511.5%1.054/96/95/71/3F-Score 76/11
    DAVITA INC.DVA$11.0B$174.56$13.6B$746.8M-114.7%-15.7815.0%1.291/94/92/71/3F-Score 73/11
    CHEMED CORPCHE$7.1B$548.20$2.5B$265.2M27.1%—13.4%1.054/97/93/71/3F-Score 66/11